Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347964 | 0.88 | VDR (0.45) | VDRHDAC3HDAC6AAK1MCHR1 | |
| SCHEMBL18374464 | 0.79 | MRGPRX4 (0.47) | VDRHDAC3HDAC6AAK1MCHR1 | |
| SCHEMBL12144437 | 0.79 | AAK1 (0.55) | VDRHDAC3HDAC6AAK1 | |
| SCHEMBL22374264 | 0.78 | RIPK1 (0.42) | — | |
| SCHEMBL2226575 | 0.78 | AAK1 (0.40) | VDRHDAC3HDAC6AAK1MCHR1 | |
| SCHEMBL22414502 | 0.77 | TNKS2 (0.41) | VDRHDAC3HDAC6AAK1 | |
| SCHEMBL20347961 | 0.76 | ALOX5AP (0.42) | AAK1 | |
| SCHEMBL27439663 | 0.75 | PDE2A (0.46) | VDRHDAC3HDAC6AAK1 | |
| SCHEMBL20347944 | 0.75 | VDR (0.42) | VDRHDAC3HDAC6MCHR1EGFR | |
| SCHEMBL20347963 | 0.75 | KDM4E (0.42) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577321-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577321-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | VDR 3125/4885HDAC3 2279/4885HDAC6 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.